In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Denali Therapeutics Inc’s stock clocked out at $14.12, down -4.34% from its previous closing price of $14.76. In other words, the price has decreased by -$4.34 from its previous closing price. On the day, 0.94 million shares were traded. DNLI stock price reached its highest trading level at $14.9025 during the session, while it also had its lowest trading level at $14.1.
Ratios:
To gain a deeper understanding of DNLI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.46 and its Current Ratio is at 8.46. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $31.
On January 07, 2025, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $31.Robert W. Baird initiated its Outperform rating on January 07, 2025, with a $31 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 06 ’25 when Ho Carole sold 12,255 shares for $20.22 per share. The transaction valued at 247,796 led to the insider holds 178,580 shares of the business.
Ho Carole sold 2,907 shares of DNLI for $60,495 on Jan 07 ’25. The Chief Medical Officer now owns 175,673 shares after completing the transaction at $20.81 per share. On Jan 06 ’25, another insider, Schuth Alexander O., who serves as the COFO and Secretary of the company, sold 12,255 shares for $20.22 each. As a result, the insider received 247,796 and left with 247,215 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNLI now has a Market Capitalization of 2050435840 and an Enterprise Value of 1272432384.
Stock Price History:
The Beta on a monthly basis for DNLI is 1.55, which has changed by -0.32017332 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, DNLI has reached a high of $33.33, while it has fallen to a 52-week low of $14.01. The 50-Day Moving Average of the stock is -27.20%, while the 200-Day Moving Average is calculated to be -39.47%.
Shares Statistics:
It appears that DNLI traded 1.06M shares on average per day over the past three months and 955170 shares per day over the past ten days. A total of 142.63M shares are outstanding, with a floating share count of 125.71M. Insiders hold about 13.43% of the company’s shares, while institutions hold 88.04% stake in the company. Shares short for DNLI as of 1741910400 were 10505627 with a Short Ratio of 8.41, compared to 1739491200 on 8685245. Therefore, it implies a Short% of Shares Outstanding of 10505627 and a Short% of Float of 8.450000000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Denali Therapeutics Inc (DNLI) is currently being evaluated by a team of 11.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.71, with high estimates of -$0.51 and low estimates of -$0.8.
Analysts are recommending an EPS of between -$2.32 and -$3.33 for the fiscal current year, implying an average EPS of -$2.86. EPS for the following year is -$2.61, with 14.0 analysts recommending between -$1.67 and -$3.16.
Revenue Estimates
Based on 17 analysts’ estimates, the company’s revenue will be $128.72M in the next fiscal year. The high estimate is $284.12M and the low estimate is $25.34M.
